ArticleBiomedical materials (Bristol, England)2017
Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections.
Article in Biomedical materials (Bristol, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.Clinical and translational medicine · 2022Trial
- Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity.Nature communications · 2026Article
- Biosynthesized silver nanoparticles prevent bacterial infection in chicken egg model and mitigate biofilm formation on medical catheters.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024Article
- Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity.Infection and drug resistance · 2024Review
- Treatment of HNSC and pulmonary metastasis using the anti-helminthic drug niclosamide to modulate Stat3 signaling activity.Journal of Cancer · 2024Article
- Gold complex compounds that inhibit drug-resistantFrontiers in antibiotics · 2023Article
- A Niclosamide-releasing hot-melt extruded catheter prevents Staphylococcus aureus experimental biomaterial-associated infection.Scientific reports · 2022Article
- Niclosamide-A promising treatment for COVID-19.British journal of pharmacology · 2022Review
- Niclosamide as a Repurposing Drug againstAntibiotics (Basel, Switzerland) · 2022Article
- Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?Current microbiology · 2021Review
- Article
- Characterization of Five Novel Anti-MRSA Compounds Identified Using a Whole-AnimalAntibiotics (Basel, Switzerland) · 2020Article
- Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening.Journal of microbiology (Seoul, Korea) · 2020Review
- Optimization of a High-Throughput 384-Well Plate-Based Screening Platform withInternational journal of molecular sciences · 2020Article
- Development of a Novel Chimeric Endolysin, Lys109 With Enhanced Lytic Activity AgainstFrontiers in microbiology · 2020Article
- Niclosamide repurposed for the treatment of inflammatory airway disease.JCI insight · 2019Article
- The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-ResistantFrontiers in microbiology · 2019Article
- Auranofin Releasing Antibacterial and Antibiofilm Polyurethane Intravascular Catheter Coatings.Frontiers in cellular and infection microbiology · 2019Article
- Niclosamide Induces Epiboly Delay During Early Zebrafish Embryogenesis.Toxicological sciences : an official journal of the Society of Toxicology · 2018Article
- Niclosamide, a Drug with Many (Re)purposes.ChemMedChem · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Device-associated and hospital-acquired infections remain amongst the greatest challenges in regenerative medicine. Furthermore, the rapid emergence of antibiotic resistance and lack of new classes of antibiotics has made the treatment of these bacterial infections increasingly difficult. The repurposing of Food and Drug Administration approved drugs for antimicrobial therapies is a powerful means of reducing the time and cost associated with drug discovery and development. In this work, niclosamide, a commercially available anthelmintic drug with recently identified antimicrobial properties, was found to prevent the formation of, and combat existing biofilms of, several relevant Gram-positive bacteria, namely strains of Staphylococcus aureus, including methicillin resistant S. aureus (MRSA), and Staphylococcus epidermidis, all common causes of hospital-acquired and device-associated infections. This anti-biofilm activity was demonstrated at niclosamide concentrations as low as 0.01 μg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.